KIT EXON 9 MUTATION

在胃肠道间质瘤（GIST）患者中，伊马替尼改善了KIT突变患者的预后。然而，获得性伊马替尼耐药性是常见的。携带外显子9-kit突变的患者可能受益于较高的伊马替尼剂量（800mg/天）。同样，伊马替尼难治性肿瘤对舒尼替尼治疗表现出敏感性。在外显子11突变的患者中没有观察到对两种治疗的改善反应。
In patients with gastrointestinal stromal tumors (GIST), imatinib has improved outcomes for patients with KIT mutations. However, acquired resistance to imatinib is common. Patients harboring exon 9 KIT mutations may benefit from higher imatinib doses (800mg/daily). Similarly, imatinib-refractory tumors showed sensitivity to sunitinib treatment. Improved responses to either treatment were not observed in patients with exon 11 mutations.